ASP Isotopes Inc

The chart remains in a Stage 4 decline with confirmed lower highs and lower lows, driven by a recent Support Failure on heavy volume. Medium-term bias is firmly bearish, but price is extended below key EMAs and in extreme oversold territory, making short-side entries untimely. Favor trimming existing positions into any bounce toward the 9/21EMA or prior support-turned-resistance zone.

• ↑Revenue surged 480% YoY to $23.8M in 2025, driven by radiopharmacy operations
• ↑Cash, equivalents & marketable securities total $333M as of Sep 30 2025 to fund growth
• ↓Net loss rose to $34.9M YTD in 2025 from $18.7M prior year